An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
We report an unusual dermatological reaction to bortezomib in a 61-year-old man with AL amyloidosis. Systemic AL amyloidosis is a rare complication of monoclonal gammopathy or myeloma in which abnormally unstable free light chains cause fibrillary deposits in organs leading to multisystem disease. The treatment of AL amyloidosis is directed at the underlying plasma cell dyscrasia and most regimes have been adapted from myeloma, but drug toxicity is more common in AL amyloidosis because of the more extensive nature of the disease. We report a patient who developed asymptomatic purple discolouration of the veins of his left arm several days after receiving the infusion in his left hand, although the infusion itself had been uncomplicated with no extravasation. The discolouration resolved completely within 2 weeks; there was recurrence on a subsequent dose of bortezomib but this also subsided spontaneously. This reaction may have been transient phlebitis or a local vasogenic reaction; its transient nature and the lack of systemic features suggest it is a benign phenomenon. There appears to be no indication for discontinuation of bortezomib treatment or dose alteration in such cases.
Shah
Anoop D
AD
Department of Haematology, Royal Free Hospital, London, UK. anoop@doctors.org.uk
Watts
Andrew J B
AJ
Mehta
Atul B
AB
Wechalekar
Ashutosh D
AD
D000686:Amyloidosis / Q000188:drug therapy* / Q000473:pathology; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D003875:Drug Eruptions / Q000473:pathology*; D006801:Humans; D007147:Immunoglobulin Light Chains; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000188:drug therapy* / Q000473:pathology; D011480:Protease Inhibitors / Q000009:adverse effects*; D011719:Pyrazines / Q000009:adverse effects*
D001897:Boronic Acids; D007147:Immunoglobulin Light Chains; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib